Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

18.222.254.247
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Interstitial Lung Disease
Journal Scan

Composite clinical outcome not improved with co-trimoxazole in idiopathic pulmonary fibrosis trial

Posted on

Co-trimoxazole did not reduce a composite outcome of time to death, transplant, or nonelective hospitalization compared with placebo in patients with moderate or severe idiopathic pulmonary fibrosis (IPF), according to a study published in JAMA.

In this double-blind, placebo-controlled, parallel randomized trial, 342 patients with IPF, breathlessness, and impaired lung function, were randomized to receive 960 mg of oral co-trimoxazole twice daily (n = 170) or matched placebo (n = 172) for between 12 and 42 months.

Out of the 342 patients who started the trial, 83% (n = 283) completed it, with a median follow-up time of 1.02 years.

-Advertisement-
-Advertisement-

Events per person-year of follow-up were 0.45 (84/186) in patients randomized to receive co-trimoxazole and 0.38 (80/209) in patients receiving placebo.

No statistically significant differences in other event outcomes, lung function, or patient-reported outcomes were found.

Patients in the co-trimoxazole group and placebo group had 696 and 640 adverse events, respectively.

Reference

Wilson AM, Clark AB, Cahn T, et al. Effect of co-trimoxazole (Trimethoprim-Sulfamethoxazole) vs placebo on death, lung transplant, or hospital admission in patients with moderate and severe idiopathic pulmonary fibrosis: The EME-TIPAC Randomized Clinical Trial. JAMA. 2020;324(22):2282–2291. doi:10.1001/jama.2020.22960.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-